Clinical Trials Logo

Clinical Trial Summary

This is an assessment of efficacy and safety of three different doses of pegylated recombinant asparaginase (PEG-rASNase) in comparison to Oncaspar® during treatment of adults with de novo acute lymphoblastic leukaemia (ALL). This study will provide first data for determining specific asparaginase doses to yield various durations of L-asparagine (ASN) depletion which are required within different treatment phases of ALL therapy.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01251809
Study type Interventional
Source medac GmbH
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 2011
Completion date May 2013

See also
  Status Clinical Trial Phase
Completed NCT03593304 - Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients Phase 2/Phase 3
Completed NCT01597219 - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Phase 2
Recruiting NCT01619124 - Osteonecroses in Pediatric Patients With ALL N/A
Recruiting NCT01272440 - A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia N/A
Completed NCT01616238 - A Study for Older Adults With Acute Lymphoblastic Leukaemia Phase 2
Recruiting NCT06037018 - Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies Phase 1
Recruiting NCT01949129 - Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia Phase 2/Phase 3
Not yet recruiting NCT06355583 - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial Phase 2